<p>SINGAPORE, May 5 (Reuters) - Impact Therapeutics (7630.HK) , a Chinese cancer-drug developer, aims to raise up to $117 million in a Hong Kong initial public offering, according to a term sheet seen by Reuters on Tuesday.</p>
<ul>
<li>Impact is offering 41.98 million shares at HK$19.75 to HK$21.75 ($2.52 to $2.78) each.</li>
<li>The deal could rise to $134 million if underwriters use an over-allotment option.</li>
<li>Six cornerstone investors, including Tencent  (0700.HK) , will buy about $35.7 million of the stock.</li>
<li>Impact expects to price the IPO on May 11 and list on May 13.  ($1 = 7.8329 Hong Kong dollars)</li>
</ul>

TCTZF

TCEHY

00700

- Impact Therapeutics, a Chinese cancer-drug developer, plans to raise up to $117 million in a Hong Kong initial public offering.  
- The company is offering 41.98 million shares priced between HK$19.75 and HK$21.75 each, with potential total proceeds of $134 million if underwriters exercise an over-allotment option.  
- The IPO is expected to be priced on May 11 and listed on May 13, with Tencent among the cornerstone investors purchasing approximately $35.7 million of the stock.

Reuters

Tencent Holdings Limited

Tencent

TENCENT

TENCENT-R

Tencent HK SDR 10to1

China's Impact Therapeutics seeks up to $117 million in Hong Kong IPO, term sheet shows